Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
Closed Posted
- Opportunity number
- PAR-25-051
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
-
- 93.121 Oral Diseases and Disorders Research
- 93.213 Research and Training in Complementary and Integrative Health
- 93.242 Mental Health Research Grants
- 93.273 Alcohol Research Programs
- 93.279 Drug Use and Addiction Research Programs
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- 93.866 Aging Research
- 93.867 Vision Research
- Funding instrument
- Cooperative Agreement
- Categories
-
- Education
- Health
- Eligible applicants
-
- Tribal Organizations (Not Federally Recognized)
- Small Businesses
- Tribal Governments (Federally Recognized)
- County Governments
- Independent School Districts
- Public or Indian Housing Auth.
- Higher Education Inst. (Public)
- Non-501(c)(3) Nonprofits
- For Profit Organizations
- Other
- City/Township Governments
- Special District Governments
- State Governments
- 501(c)(3) Nonprofits
- Higher Education Inst. (Private)
- Full announcement
Opportunity details come from Grants.gov. Updated .
Synopsis
The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.
Files
| File | Type | Posted |
|---|---|---|
| PAR-25-051-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity